abt-199 has been researched along with Leukemia--Prolymphocytic--B-Cell* in 3 studies
3 other study(ies) available for abt-199 and Leukemia--Prolymphocytic--B-Cell
| Article | Year |
|---|---|
Venetoclax induces deep and durable minimal residual disease-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia.
B-cell prolymphocytic leukaemia (B-PLL) is an aggressive B-cell lymphoproliferative disease with few clinically proven targeted treatments. Due to the rarity of the condition, there is a paucity of clinical trial data and none that involve targeted inhibitors. We present a unique case of relapsed refractory B-PLL treated to a sustained minimal residual disease-negative remission with venetoclax monotherapy, to add to the current evidence base and rationale for future studies using BCL-2 inhibitors in B-PLL. Topics: Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, B-Cell; Neoplasm, Residual; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Tumor Suppressor Protein p53 | 2022 |
B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, B-Cell; Receptors, Antigen, B-Cell; Sulfonamides | 2020 |
Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
Topics: Adenine; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Substitution; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Retreatment; Rituximab; Signal Transduction; Sulfonamides; Treatment Outcome | 2019 |